SpringWorks Therapeutics, a Pfizer-conceived, mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, launched today with news of promising investigational therapies, including one for neurofibromatosis. The Children’s Tumor Foundation is collaborating with this new company to connect the NF community with these much-needed therapies.
SpringWorks represents an innovative approach to drug development, with a business model designed to deliver both social and financial returns via partnerships with a variety of stakeholders, including scientists, biopharmaceutical partners, patient groups, funders and philanthropists. It is being launched with funding from Pfizer, Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, and LifeArc. SpringWorks Therapeutics also has rights to four clinical-stage experimental therapies from Pfizer.
One of those therapies is of benefit to patients with plexiform neurofibromatosis. SpringWorks Therapeutics is planning to initiate a Phase 3 program to establish safety and efficacy of its MEK 1/2 inhibitor (PD-0325901) in the NF1 population, in collaboration with the Children’s Tumor Foundation in order to enable the needs of the patient community.
MEK inhibitors have shown encouraging activity in reducing tumor size in clinical studies, a result of CTF’s investment in the NF Preclinical Consortium. The groundbreaking work of that consortium demonstrated that MEK inhibitors have significant impact on tumor size, and that work now informs the MEK studies that SpringWorks is moving forward.
Read the full press release here.
Read more at Bloomberg.
